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Abstract
Background: Beta thalassemia major requires regular blood transfusions and iron chelation to
alleviate the harmful accumulation of iron. Evidence on the efficacy and safety of the available
agents, desferrioxamine and deferiprone, is derived from small, non-comparative, heterogeneous
observational studies. This evidence was reviewed to quantitatively compare the ability of these
chelators to reduce hepatic iron.
Methods: The literature was searched using Medline and all reports addressing the effect of either
chelator on hepatic iron were considered. Data were abstracted independently by two
investigators. Analyses were performed using reported individual patient data. Hepatic iron
concentrations at study end and changes over time were compared using ANCOVA, controlling
for initial iron load. Differences in the proportions of patients improving were tested using χ2.
Results: Eight of 11 reports identified provided patient-level data relating to 30 desferrioxamine-
and 68 deferiprone-treated patients. Desferrioxamine was more likely than optimal dose
deferiprone to decrease hepatic iron over the average follow-up of 45 months (odds ratio, 19.0,
95% CI, 2.4 to 151.4). The degree of improvement was also larger with desferrioxamine.
Conclusions: This analysis suggests that desferrioxamine is more effective than deferiprone in
lowering hepatic iron. This comparative analysis – despite its limitations – should prove beneficial
to physicians faced with the challenge of selecting the optimal treatment for their patients.
Background
The thalassemias are a group of inherited disorders of he-
moglobin [1], the most severe form of which is beta tha-
lassemia major. Improvements in the management of
patients with thalassemia major in the past four decades
have resulted in "one of the most dramatic alterations in
morbidity and mortality associated with a genetic disease"
[2]. Regular red blood cell transfusions extend survival,
eliminate complications of anemia, inhibit bone marrow
hyperactivity, and support normal growth and develop-
ment in patients with thalassemia major [3]. Unfortunate-
ly, regular transfusions also lead to the accumulation of
tissue iron, loading the body's organs to the point of dys-
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function and finally death in the second or third decade of
life if left untreated [4].
To alleviate iron loading, chelating agents such as desfer-
rioxamine (Desferal®) and, most recently, deferiprone
(Ferriprox®) are available. As a complement to frequent
blood transfusions, proper iron chelation therapy further
improves the quality of the patient's life and extends sur-
vival, impeding iron loading complications.
Successful management of thalassemia major relies upon
accurate assessment of body iron burden. Several indirect
assessment methods are available, among which are
measurement of serum ferritin levels, urinary iron excre-
tion, and hepatic iron quantification. While no one meth-
od is superior for all clinical scenarios, until recently
measurement of hepatic iron stores – through liver biopsy
or magnetic susceptometry – has provided the most quan-
titative, specific and sensitive method for determining the
body iron burden in patients with thalassemia major and
was considered the reference method for comparison with
other techniques [2,4]. In the future, the newer advanced
magnetic-resonance techniques, which allow for the as-
sessment of both liver and cardiac iron, might provide an
even more accurate assessment of total body iron [5].
Measurement of the magnitude of iron loading is useful in
evaluating the effectiveness of the chelating agent, cali-
brating patient-specific treatment, and, in clinical re-
search, as a determinant of clinical outcome.
The literature on desferrioxamine and deferiprone lacks
consensus on their comparative effectiveness and even on
the methods for its quantification. The current evidence is
comprised of many small non-comparative studies that
evaluate the efficacy of a chelator in the short- or, more
rarely, long-term. Moreover, a significant impediment to
comparing study outcomes is variation in the method em-
ployed to measure iron burden. Several systematic reviews
of the literature have been published [2,6–8]. None of
them are quantitative comparisons of the efficacy of the
primary chelators. We undertook a quantitative review of
the literature to estimate the effectiveness of desferrioxam-
ine and deferiprone in decreasing hepatic iron concentra-
tions (HIC) in thalassemia major.
Methods
Search strategy and data extraction
All studies of desferrioxamine and deferiprone usage in
thalassemia major patients – whether randomized, blind-
ed, comparative, case series, or cross-over – irrespective of
language were considered eligible for inclusion in the
analysis. Although preference is usually given to rand-
omized controlled trials – as they provide the strongest,
least biased evidence of efficacy – the scanty information
available for thalassemia forced us to consider all study
types. Indeed, to our knowledge, only one randomized
controlled trial comparing desferrioxamine and de-
feriprone has been conducted and results for that study
are incomplete as the trial was terminated prematurely
and has not been reported in full [9–11].
The National Library of Medicine's computerized biblio-
graphic database (Medline 1966 to December 1999) was
searched using a combination of the following keywords:
thalassemia, serum ferritin, urinary iron excretion, hepatic
iron, liver, chelation therapy, iron chelation, iron chelat-
ing agents, desferal, desferrioxamine, deferoxamine, L1
oral chelate, deferiprone and 1,2-dimethyl-3-hydroxypy-
rid-4-one. The Medline search was augmented by manual-
ly searching the reference lists of retrieved studies and
reviews and by reviewing abstracts from conference pro-
ceedings. The studies identified were carefully evaluated
for eligibility; they were included if they (i) enrolled sub-
jects with thalassemia major – irrespective of age at diag-
nosis, treatment initiation or study start nor of treatment
history in terms of transfusion regimen or iron chelation;
(ii) followed patients treated with either desferrioxamine
administered subcutaneously or intravenously or oral de-
feriprone; and (iii) measured hepatic iron concentrations
to evaluate treatment efficacy. Studies aimed at comparing
the relative performance of different measurement tech-
niques (e.g., liver biopsy versus MRI) were excluded. Ab-
stracts that provided sufficient information on the
endpoint under consideration were retained for the anal-
ysis. Duplications were identified and only the original or,
if pertinent, most extensive report was included. No exclu-
sions were implemented on the basis of sample size, study
quality or study duration.
Details on study design, length of follow-up, number of
patients included, patient age, presence of iron overload-
related complications at study start, prior and current iron
chelation (drug, route, dose), use of concomitant medica-
tion and outcome measures were extracted independently
by two investigators using a standardized electronic data
collection form. Investigators were not blinded to journal,
author, institution or treatment. All differences in extract-
ed data were resolved by consensus between the two ex-
tractors prior to locking the database.
Statistical analysis
The main analyses were conducted using individual pa-
tient level data, as the majority of studies reported this lev-
el of detail. For the purpose of these analyses, all HIC had
to be converted from the original value to a common
measurement unit. We opted for mg/g dry liver weight.
For each patient, we calculated the absolute change in HIC
over the study period and a "responder" was defined as
showing any improvement. The relative change was calcu-
lated as the absolute change divided by the baseline HIC.BMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/4
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The mean HIC at study end was calculated for each treat-
ment. As initial hepatic iron load was greater, on average,
in patients receiving desferrioxamine, the comparison of
the means needed to take this into account. This was done
by carrying out an ANCOVA, controlling for HIC at base-
line. A second analysis was conducted to evaluate the pro-
portion of responders, and the χ2-test was used to test for
differences in these proportions. The odds ratio of im-
provement and its 95% confidence interval were also cal-
culated. Next, for the subset of patients who showed
improvement over time, the mean relative change in HIC
was compared.
Although no fixed dose of either treatment is optimal for
all patients [12], an attempt was made to differentiate
what would generally be considered a suboptimal dose
for each treatment in line with current treatment recom-
mendations. For desferrioxamine, this was defined as less
than 40 mg/kg/day. For deferiprone, the corresponding
threshold was 75 mg/kg/day. It should be noted that in-
formation on the specific dose used by individual patients
was not provided for the majority of the studies, where the
dose varied over a certain range. Rather than ignore the
potential impact of dose on the outcome measure, we as-
signed the mean dose reported for the entire study popu-
lation to each individual within a particular study.
Analyses were carried out by dose.
Finally, additional analyses were conducted to explore the
impact on the odds of improvement of including the few
studies that provided summary information at the study
level only.
We considered a p-value less than 0.05 to be significant
for all statistical tests. No correction for multiple compar-
isons was made. Analyses were carried out with SAS ver-
sion 6.12 for Windows.
Role of funding source
The funding source had no role in the collection, analysis,
or interpretation of the data.
Results
After the first screening of titles and abstracts, 167 poten-
tially relevant articles were identified (a list of all referenc-
es is available from the authors). An in-depth review of
the full text articles, led us to exclude 106 articles for the
following reasons: review article (n = 18), study sample
did not include patients with thalassemia major (n = 21),
wrong treatment mode (e.g., desferrioxamine intramuscu-
lar or bolus injection, n = 12), wrong endpoints (e.g.,
pharmacokinetic studies, n = 32), study presented insuffi-
cient data to be extracted (n = 18), and other (n = 5). Elev-
en of the remaining 61 articles contained information on
HIC and are therefore the subject of this analysis (Table 1)
[11,13–22].
Eight of the 11 studies provided data at the individual pa-
tient level; relating to 98 patients in total, of which 30 and
68 were treated with desferrioxamine and deferiprone, re-
spectively (the individual patient data are available from
the authors). Two of the additional reports [11,18] pro-
vide results in abstract form only. Moreover, results for
one of these remain partial due to study discontinuation
[11].
Table 1: Characteristics of the 11 studies containing information on hepatic iron concentrations in patients with thalassemia major
First Author Year of
 Publication
Study† 
Design
Mean Study
 Duration 
(months)
Number 
of
 Patients
Mean 
Age
 (years)
Treatment Abstract 
alone
Individual 
Patient
 Data available
Hoffbrand AV 1979 Clinical trial 13* 31 16* DFO X
Janka GE 1981 Case series 13* 5 7 DFO X
Aldouri MA 1987 Case series 96 51 19 DFO X
Maurer HS 1988 Clinical trial 72* 16 10* DFO X
Olivieri NF 1995 Clinical trial 37 21 22 L1 X
Olivieri NF 1997 RCT 33 37 NA L1 vs DFO X
Longo F 1998 Clinical trial 24 52 17 L1 X
Mazza P 1998 Clinical trial 22 29 NA L1 X
Olivieri NF 1998 Case series 55 18 18* L1 X
Tondury P 1998 Case series 86 11 23 L1 X
Diav-Citrin O# 1999 Case series 51* 19 24 L1
* In cases where the mean was not provided, either the median or the midpoint of the range was used as an approximation. † Studies were classified 
as "clinical trials" if there was evidence of the use of a formal study protocol, and if ethics committee approval and informed consent were obtained. 
# Although this study has been withdrawn from the scientific literature as of April 22, 2002, it was decided not to exclude this study from the anal-
ysis as it has been relied upon in the literature. DFO Desferrioxamine; L1: deferiprone; NA: not availableBMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/4
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Substantial variation in study design and execution was
detected. Moreover, patients differed considerably with
respect to disease and treatment history. For example, for
several of the deferiprone studies [17–22] it was specified
that patients had been exposed previously to desferriox-
amine but had failed, usually due to non-compliance. Al-
though the length of the observation period varied
notably among studies (range: 13 to 96 months), it is fair-
ly balanced between treatments, with a mean duration of
about 45 months for both groups (2.9 years for desferri-
oxamine and 3.3 years for deferiprone). In many cases,
the data reported related to a small subset of the investiga-
tor's patient population who continued treatment for a
prolonged period of time and for whom long-term infor-
mation on changes in iron load was available. In that re-
spect, the information reported in the literature might
very well be biased. As there is little information in the pa-
pers as to how the patients with serial hepatic iron infor-
mation were selected, the impact of this potential
selection bias cannot be identified.
Clinical characteristics of the study patients are summa-
rized in Table 2. Although all studies included predomi-
nantly children and young adults with thalassemia major,
patients treated with desferrioxamine were significantly (p
= 0.03) younger (mean: 13 yrs) than those treated with
deferiprone (mean: 21 yrs). The severity of the hepatic
iron overload at study entry differed greatly between pa-
tients, ranging from 0.5 to 115.0 mg/g dry weight (mean:
21.4 mg/g, SD: 17.6 mg/g), and was also significantly (p <
0.0001) higher for the desferrioxamine-treated patients
(mean: 36.5 mg/g, SD: 21.3 mg/g) compared to de-
feriprone-treated patients (mean: 14.8 mg/g, SD: 10.2 mg/
g). All 30 patients treated with desferrioxamine received
the optimal dose; that is, 40 mg/kg/day or higher com-
pared to about two thirds of patients treated with de-
feriprone (48 out of 68).
Hepatic iron concentrations at endpoint
The mean HIC at endpoint, considering all patients, was
14.4 mg/g. Based on clinical experience with hereditary
hemochromatosis, the optimal range for HIC in patients
Table 2: Clinical characteristics of patients in studies included in the meta-analysis
First Author Number of 
patients with
 hepatic iron 
information
Treatment & 
mean dose
 (mg/kg/day)
Initial ferritin level,
 mean (SD) (µg/L)
Hepatic iron
 concentration, Mean (SD)
Measurement
 unit
Initial Final
Hoffbrand AV 4 DFO 57† 10,683 (NA) 76.7 (30.4) 56.9 (42.9) µg/mg dry
Janka GE 2 DFO 103§ 3,294 (1,462)* 26.9 (16.0) 9.9 (5.5) g/kg dry
Aldouri MA 12 DFO 50‡ 5,885 (3,245)* 2945 (900) 857 (435) µg/100 mg dry, 
chemical
Maurer HS 12 DFO 85§ 3,164 (1,321)* 3,275.5 
(1,225.1)¶
1508.3 
(887.3)
µg/100 mg dry
Olivieri NF 21 L1 75 3,975 (3,510) 81.9 (51.6) 46.7 (26.4) µmol/g wet
Olivieri NF 37 L1 75 NA L1: 8.9 (1.2) L1: 13.7 (1.2) mg/g dry
DFO 37 DFO: 6.9 (0.9) DFO: 7.9 
(1.3)
Longo F 52 L1 75 1,897 (NA) 1430 (NA) 2029 (NA) µg/g
Mazza P 20 L1 70 4,495 (2,644) 16.1 (12.4) 20.4 (20.0) mg/g dry
Olivieri NF 18 L1 75 4,455 (3,569) 89.1 (50.8) 65.4 (33.5) µmol/g wet
Tondury P 9 L1 82‡ 2,862 (1,390)** 7.6 (4.4) 8.9 (5.6) mg/g dry
Diav-Citrin O 19 L1 75 3,122 (NA) 14.3 (7.2) 10.0 (6.1) mg/g dry
* Mean for the entire study population; not specific to the subgroup of patients for which hepatic iron information is available. 
 ** Mean for subgroup of 7 patients. 
† Calculated using midpoint of range of total daily dose provided and individual patients' weight estimates derived from gender-specific weight 
charts. 
‡ Midpoint of range. 
§ Maximum dose. 
¶ Values read from graph. Scaling error in the original report has been corrected. 
DFO Desferrioxamine; L1: deferiprone; NA: not available.BMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/4
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with thalassemia major is considered to be between 3.2
and 7.0 mg/g dry weight, above which patients run an in-
creased risk of complications, including hepatic fibrosis,
diabetes mellitus, and – at concentrations above 15 mg/g
– of cardiac disease and early death [2]. At the end of the
respective observation periods, 67.3% of all treated pa-
tients still had an HIC over 7.0 mg/g, compared to 85.7%
of patients at the start.
Figure 1 clearly illustrates the anticipated correlation be-
tween initial and final HIC and, therefore, the importance
of controlling for initial hepatic iron load in comparative
analyses. Hepatic iron load at study end – controlling for
initial hepatic iron load – was found to be significantly
lower in desferrioxamine-treated patients (adjusted mean:
6.4 mg/g), compared to patients treated with either opti-
mal dose (15.3 mg/g) or low dose (24.3 mg/g) de-
feriprone (overall p < 0.0001; p = 0.06 and p = 0.0002 for
pairwise comparisons of desferrioxamine vs optimal and
low dose deferiprone, respectively).
Changes in hepatic iron concentration over time
Overall, 65 of the 98 patients showed an improvement in
HIC. Patients treated with desferrioxamine were more
likely to improve than patients treated with optimal dose
(OR: 19.0; 95%CI: 2.4–151.4) or low dose (OR: 53.9;
95%CI: 6.0–483.7) deferiprone within the study observa-
tion periods (Figure 2). Controlling for hepatic iron load
at baseline did not affect these results.
Figure 1
Initial and final hepatic iron concentrations for the 98 patients included in the main analyses by treatment and
dose category. Hepatic iron concentrations are expressed in mg/g dry liver weight. The dotted lines indicate the cut-off (7.0
mg/g) above which patients run an increased risk for complications due to hepatic iron overload.
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Among the 65 patients who improved over time, the he-
patic iron load decreased significantly more in desferriox-
amine-treated patients: by 60.2% (an average of 15.8 mg/
g), compared with 45.3% (12.4 mg/g) in deferiprone op-
timal dose and 33.5% (10.7 mg/g) in deferiprone low
dose (overall p < 0.01; findings confirmed in pairwise
comparisons).
Inclusion of additional studies
We explored the impact of the three studies that did not
provide individual patient data by including them in ad-
ditional analyses. To allow for this analysis, "improve-
ment" had to be defined for each study, as results were
reported in slightly different ways depending on the
study. Patients in the study conducted by Diav-Citrin [22]
were all treated with deferiprone and we defined improve-
ment as HIC that were reduced or maintained at less than
7 mg/g of dry weight liver tissue. A threshold of 15 mg/g
tissue iron had to be used instead for the comparative
study conducted by Olivieri and colleagues due to how
these researchers summarize the results [11]. For the study
by Longo and colleagues [18], patients receiving de-
feriprone who were in a negative or stable iron balance at
the end of the observation period were considered to have
improved.
The odds ratios presented in Figure 2 demonstrate that the
findings remain largely in favor of desferrioxamine in all
scenarios examined; that is, the 95% CI do not include 1.
Figure 2
Odds ratios for improvement in hepatic iron concentrations over time, presented on a logarithmic scale. The
odds ratios for the main analysis are provided for each dose category of L1 separately and combined. The odds ratios for the
sensitivity analysis are presented for inclusion of each of the additional studies one by one and combined.
10 100 1000
Main analysis 
+ Longo ‘98
+ Olivieri ‘97
+ Diav-Citrin, Longo, Olivieri 
Desferal vs L1 low dose
Sensitivity analysis:
+ Diav-Citrin ‘99
Desferal vs L1 high dose
Desferal vs L1 (both doses)
1
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Discussion
Based on analyses of individual patient data from eight
studies reporting on changes in HIC over time, desferriox-
amine seems to be more effective than deferiprone in low-
ering hepatic iron in patients with thalassemia major.
Indeed, the analyses indicate that desferrioxamine not
only increases the likelihood of lowering hepatic iron
load, but also tends to induce larger reductions in hepatic
iron among responders, even after controlling for the im-
balance in HIC at study initiation. These results remain
when including data from three additional studies that
provided summary information only.
There are several important qualifications to these results.
The doses of deferiprone – even in the optimal dose group
– are relatively low, compared to the desferrioxamine dos-
es, which in most studies are well above the recommend-
ed 40 mg/kg/day. This is important in light of the strong
connection between the dose of the iron chelator and the
amount of iron excreted. On the other hand, the results
from the only randomized trial suggest that even at rela-
tively low doses, desferrioxamine outperforms de-
feriprone [11]. Moreover, the toxic:therapeutic ratio of
deferiprone is reportedly low; doses of 100 mg/kg/day
have resulted in bone marrow toxicity in animals and hu-
mans. Second, liver iron concentration is only one of the
outcome parameters considered in the studies included in
our analyses and in several cases only available for a small
subset of the entire study population [13–16,21]. As it is
impossible to determine how or why these particular pa-
tients were selected for repeated liver biopsy, the magni-
tude and direction of the potential bias this may have
caused cannot be ascertained. Finally, as several of the pa-
tients included in the deferiprone studies had previously
failed desferrioxamine treatment, due to non-compliance
or other reasons, it could be postulated that they are more
likely to do badly on deferiprone as well. Despite the fact
that compliance is improved on deferiprone, this high-
lights the dangers of assuming that this drug, with poten-
tial toxicity greater than that of desferrioxamine, should
be implemented in patients struggling with desferrioxam-
ine, as proposed by some clinicians.
Comparison with specific findings in the literature is dif-
ficult because of the vast differences in study objectives,
patient populations studied, parameters evaluated, and
analytical approach. Broadly speaking, however, our find-
ings are in accord with other published data. Several sys-
tematic, qualitative reviews [2,8,23,24] highlight the
clinical benefits of desferrioxamine treatment and, with
respect to iron loading, acknowledge its ability to main-
tain harmless hepatic iron levels in properly chelated pa-
tients. The most recent of these reviews also corroborate
our finding that deferiprone-treated patients do not expe-
rience the same degree of improvement in hepatic iron
levels as desferrioxamine-treated patients [2,6] and some
project further doubt on the long-term implications of de-
feriprone treatment [8].
Measurement of HIC has been established in the field as
the reference method for assessing total body iron burden
in thalassemia major, and therefore preferred for research
purposes. Nevertheless, the methods of measurement
(namely liver biopsy and superconducting quantum inter-
face device or SQUID) are often infeasible in everyday
practice. Liver biopsies are neither a convenient [23] nor
patient-preferred [2,19,25] means of monitoring efficacy
in iron chelation therapy. Even less viable an alternative is
the new, noninvasive SQUID, which is both prohibitively
expensive and restricted to only three especially-equipped
sites: one in Germany, one in Italy and one in the United
States [2,8]. Such constraints lie at the root of the limited
number of published studies that use HIC as the efficacy
criterion, despite its importance to clinical investigation.
It should also be noted that the newer advanced magnetic-
resonance techniques might provide a more accurate as-
sessment of total body iron than liver biopsy or SQUID
because iron pools in the heart and liver may be separate
and this newer technique allows for the simultaneous as-
sessment of both hepatic and myocardial iron concentra-
tions [5].
The diversity in study design and execution as well as the
reporting of the results posed many challenges for this
analysis. The literature is dominated by observational
studies and nonrandomized clinical trials performed on
small selected patient cohorts, thereby making a tradition-
al meta-analysis impossible to complete. The content of
the studies is noteworthy as well. Many studies were car-
ried out without treatment protocols while others report-
ed results only for subgroups – usually undefined. Still
other studies reported outcomes only graphically, that is,
without providing the precise values. A further challenge
to evaluating hepatic iron as reported in the published
data is the significant variation in measurement units and
assessment values (i.e., dry or wet), as Table 2 illustrates.
For example, the wet-to-dry weight liver iron conversions
require an assumption of liver water content, which rang-
es from 60 to 75 percent in the literature [26]. Due to in-
complete information, our analyses do not take into
account some potentially important patient characteris-
tics, such as duration of treatment administration or pres-
ence of iron-induced complications, nor the patients'
transfusion regimens, all of which are used to calibrate ap-
propriate dose prescriptions and may influence efficacy
outcomes [12,21,25,27].
Given the methodological caveats and the heterogeneity
of study characteristics, one could legitimately question
the appropriateness of pooling the results on hepatic ironBMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/4
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concentration across studies. Physicians must still select
the optimal treatment for their patients, however, regard-
less of the quality of the evidence. In the absence of large
randomized well-controlled trials, it was felt that this
analysis, despite its limitations, would summarize the ev-
idence in a useful way. To avoid any misleading conclu-
sions we have sought to be completely transparent about
the underlying assumptions and caveats of the analysis.
To many, deferiprone may not appear as a first-line chela-
tor but rather as an alternative to desferrioxamine should
the latter not be usable. From that point of view, compar-
ative effectiveness may not be an issue. The analysis pre-
sented here casts doubt, however, even on this premise
that deferiprone offers a useful alternative to desferriox-
amine in patients who have difficulties with the adminis-
tration of a parenteral drug.
Since this review was completed, two important new stud-
ies have become available. In the first study, 144 patients
with thalassemia major and relatively low serum ferritin
concentrations (1,500 – 3,000 ng/mL) were randomized
to either deferiprone (n = 71) or desferrioxamine (n = 73)
and followed for one year [28]. Although, the primary ef-
ficacy measure was the reduction of serum ferritin, HIC
was assessed in a small subgroup of patients willing to un-
dergo repeat liver biopsy: 21 in the deferiprone and 15 in
the desferrioxamine group. No significant difference in
the reduction of HIC or the presence of liver fibrosis was
detected in this subgroup of patients, leading the authors
to conclude that both treatments have a similar chelating
effect over a relatively short time period. This apparent
comparability in reduction of HIC is in conflict, however,
with the results of another recently published study. A
case-control study in 15 patients treated with deferiprone
(cases) and 30 patients treated with desferrioxamine (con-
trols) matched for age and serum ferritin levels, demon-
strated that deferiprone appears to be more effective than
desferrioxamine in removal of myocardial iron despite sig-
nificantly higher HIC in the deferiprone group [5]. Al-
though a larger prospective trial is needed to confirm the
results, these findings would suggest that a combination
of both drugs may be most beneficial in order to reduce
both hepatic and myocardial concentrations of iron.
Conclusions
It has been said that a meta-analysis is only useful until
the next good trial comes along [29]. In the case of iron
chelation therapy for patients with thalassemia major, the
addition of any good prospective randomized control trial
documenting the impact of treatment on body iron (he-
patic and/or myocardial) would contribute measurably to
the evaluation of the long-term implications of treatment
with deferiprone, compared to desferrioxamine. Until
such a study becomes available, we present this compre-
hensive and quantitative review of the evidence to aid pa-
tients with thalassemia major and their physicians in
clinical judgment and treatment decisions.
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